Proteomics International Laboratories Ltd (PIQ.XA)
Cboe AU · AUD
A$0.115 (-4.17%) as of
Key statistics
- EPS (TTM)
- -0.0390
- 52-week range
- 0.0960 – 0.8450
- Beta
- -0.36
- Revenue (TTM)
- 3.37M
- Profit margin
- -253.98%
- Volume
- 67.86k
About Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, and India. It provides PromarkerD, a blood test to predict chronic kidney disease in people with type 2 diabetes. The company's products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. The company also offers analytical services, such as biomarker discovery and validation, biosimilars/biologics characterisation, and pharmacokinetic testing. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Nedlands, Australia.
- Headquarters
- Nedlands, WA, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.